Scribble

AVLN share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Price change

The price of AVLN shares has increased $0.39 since the market last closed. This is a 1.37% rise.
Closed at $28.78.

The stock has since risen $0.57 in after-hours trading.

Key terms

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Market cap: $1.20B

A market capitalization between $300 million and $2 billion places AVLN in the small capitalization category.

Key terms

Smart score

May 26, 2026 12:06pm ET Opening Day: SpaceX submits S-1 for Nasdaq IPO by TipRanks May 26, 2026 10:52am ET Avalyn Pharma initiated with an Outperform at Evercore ISI by TipRanks May 26, 2026 5:21am ET Avalyn Pharma initiated with an Overweight at Morgan Stanley by TipRanks May 25, 2026 11:21am ET Avalyn Pharma initiated with a Buy at Guggenheim by TipRanks May 25, 2026 7:26am ET Analyst Reiterates Buy on Avalyn, Citing Inhaled IPF/PPF Pipeline and Multiple Revenue Streams to Support $52 Price Target by TipRanks May 25, 2026 7:05am ET Avalyn Pharma initiated with a Buy at Jefferies by TipRanks May 25, 2026 6:45am ET Avalyn Pharma initiated with a Buy at Guggenheim by TipRanks May 05, 2026 10:04pm ET Major Insider Move Signals Big Confidence in Avalyn Pharma by TipRanks May 04, 2026 11:51am ET Opening Day: Pershing Square listings open soft in market debut by TipRanks May 01, 2026 10:02pm ET Major Insider Moves Signal Growing Confidence in Avalyn Pharma by TipRanks Apr 30, 2026 2:10pm ET Avalyn Pharma indicated to open at $25.25, IPO priced at $18.00 by TipRanks Apr 30, 2026 1:58pm ET Avalyn Pharma opens at $26.00, IPO priced at $18.00 by TipRanks Apr 29, 2026 11:35pm ET Avalyn Pharma 16.67M share IPO priced at $18.00 by TipRanks

May 27, 2026 8:00am ET Avalyn to Participate in the Jefferies Global Healthcare Conference by GlobeNewswire May 21, 2026 8:00am ET Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 by GlobeNewswire May 05, 2026 4:01pm ET Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference by GlobeNewswire May 01, 2026 4:01pm ET Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares by GlobeNewswire Apr 29, 2026 9:00pm ET Avalyn Announces Pricing of Upsized Initial Public Offering by GlobeNewswire Apr 27, 2026 8:00am ET Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury by GlobeNewswire

1-year income & revenue

AVLN total revenue: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
AVLN net income: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
AVLN earnings per share: temporarily unavailable. We are sorry, but this information is temporarily unavailable.

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

How competitors are chosen

AVLN's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
Market cap: $1.20B

A market capitalization between $300 million and $2 billion places AVLN in the small capitalization category.